{"id":13781,"date":"2022-12-22T10:58:42","date_gmt":"2022-12-22T10:58:42","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/"},"modified":"2026-02-11T09:51:11","modified_gmt":"2026-02-11T09:51:11","slug":"sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni","status":"publish","type":"post","link":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/","title":{"rendered":"Sygnature Discovery s’associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni."},"content":{"rendered":"

Sygnature Discovery rejoint quatre des dix plus grandes soci\u00e9t\u00e9s pharmaceutiques mondiales, Cancer Research Horizons<\/a> , le Manchester Cancer Research Centre (MCRC) et plus de 20 organismes de recherche sous contrat (CRO) pour soutenir l\u2019innovation en oncologie \u00e0 travers le deuxi\u00e8me programme de d\u00e9veloppement en oncologie (ODP2). Cette initiative vise \u00e0 acc\u00e9l\u00e9rer le d\u00e9veloppement d\u2019innovations \u00e0 fort impact dans le domaine du cancer, la mise en \u0153uvre du programme \u00e9tant supervis\u00e9e par Lean Life Science<\/a> .<\/strong><\/span><\/h3>\n
\"Sygnature

Sygnature Discovery sera partenaire du deuxi\u00e8me programme de d\u00e9veloppement en oncologie (ODP2).<\/p><\/div>\n

Les chercheurs et les jeunes entreprises britanniques d\u00e9veloppant une innovation cibl\u00e9e en oncologie peuvent candidater au programme et b\u00e9n\u00e9ficier d\u2019un accompagnement personnalis\u00e9\u00a0: \u00e9valuation scientifique par des experts, conception d\u2019\u00e9tudes cliniques, analyse des lacunes techniques, mod\u00e9lisation de la valeur financi\u00e8re et commerciale et planification int\u00e9gr\u00e9e du projet. Les candidatures ont \u00e9t\u00e9 ouvertes fin novembre et un comit\u00e9 de s\u00e9lection du programme retiendra les propositions les plus prometteuses en janvier\u00a02023. <\/p>\n

Jane Kendrew, directrice de l\u2019oncologie translationnelle chez Sygnature Discovery<\/a> , repr\u00e9sentera l\u2019entreprise au sein de ce panel d\u2019experts et apportera son expertise en consultation avec ses coll\u00e8gues de Sygnature issus de domaines sp\u00e9cialis\u00e9s, notamment la DMPK, la pharmacologie in vivo<\/em> , la chimie et les biosciences.<\/p>\n

Jane commente\u00a0: \u00ab\u00a0Le niveau de recherche de m\u00e9dicaments innovants actuellement en cours au Royaume-Uni est exceptionnel. Je suis ravie de pouvoir y contribuer modestement en tant qu\u2019experte au sein du panel ODP2.\u00a0\u00bb<\/em><\/span><\/p>\n

Aper\u00e7u du deuxi\u00e8me programme de d\u00e9veloppement en oncologie <\/span><\/strong><\/h2>\n

ODP2 se compose de trois parties, comme suit\u00a0:<\/p>\n

    \n
  1. Une masterclass d\u2019une journ\u00e9e en immersion totale et l\u2019opportunit\u00e9 de d\u00e9couvrir comment les innovations sont \u00e9valu\u00e9es par l\u2019industrie pharmaceutique<\/li>\n
  2. Trois jours d\u2019immersion compl\u00e8te dans l\u2019approche Lean Life Science, qui a fait ses preuves en mati\u00e8re de d\u00e9veloppement de produits oncologiques et d\u2019obtention d\u2019investissements, offrant \u00e9galement l\u2019opportunit\u00e9 d\u2019\u00e9changer directement avec des experts pharmaceutiques et des CRO.<\/li>\n
  3. Sur candidature, les participants s\u00e9lectionn\u00e9s travaillent en \u00e9troite collaboration avec les partenaires pour cr\u00e9er et valider les plans int\u00e9gr\u00e9s n\u00e9cessaires \u00e0 la r\u00e9ussite du d\u00e9veloppement et \u00e0 l\u2019attraction de financements potentiels.<\/li>\n<\/ol>\n

    R\u00e9alis\u00e9 par une \u00e9quipe unique de professionnels chevronn\u00e9s de la recherche et du d\u00e9veloppement en oncologie, ainsi que de sp\u00e9cialistes du commerce et de l\u2019investissement, ODP2 vise \u00e0 identifier, \u00e0 r\u00e9duire les risques et \u00e0 catalyser les innovations commercialement viables bas\u00e9es au Royaume-Uni afin d\u2019am\u00e9liorer le diagnostic et le traitement du cancer, ainsi que d\u2019acc\u00e9l\u00e9rer la transposition des nouvelles recherches sur le cancer au b\u00e9n\u00e9fice des patients.<\/p>\n

    \u00c0 propos de Sygnature Discovery<\/strong><\/span><\/h2>\n

    Sygnature Discovery est une CRO de premier plan, sp\u00e9cialis\u00e9e dans la d\u00e9couverte de m\u00e9dicaments en oncologie. L\u2019entreprise se concentre sur la r\u00e9alisation de projets int\u00e9gr\u00e9s de d\u00e9couverte de m\u00e9dicaments<\/a> gr\u00e2ce \u00e0 des \u00e9quipes interdisciplinaires et hautement qualifi\u00e9es travaillant au sein d\u2019un m\u00eame site. Forte d\u2019une solide exp\u00e9rience, elle a men\u00e9 \u00e0 bien vingt et un projets de d\u00e9couverte de m\u00e9dicaments jusqu\u2019aux essais cliniques (phases I, II et III) au cours des onze derni\u00e8res ann\u00e9es. Parmi ces projets, on peut citer le STP938, l\u2019inhibiteur de CTPS1 exp\u00e9rimental le plus avanc\u00e9 au monde pour le traitement des lymphomes B ou T r\u00e9cidivants ou r\u00e9fractaires<\/a> , r\u00e9cemment \u00e9valu\u00e9 dans le cadre d\u2019un essai de phase I\/II. <\/p>\n

    \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":13782,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"category":[817,949,823],"tags":[951,963,969,955,959,961,967,953,965,957],"class_list":["post-13781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-domaines-therapeutiques","category-modeles-doncologie","category-oncologie","tag-accelerer-les-innovations-novatrices-en-matiere-de-cancer","tag-approche-lean-life-science-pour-les-actifs-en-oncologie","tag-avancees-majeures-en-oncologie-realisees-au-royaume-uni","tag-collaboration-avec-des-entreprises-pharmaceutiques-mondiales","tag-examen-par-un-panel-dexperts-redige-par-jane-kendrew","tag-masterclass-immersive-en-evaluations-pharmaceutiques","tag-partenariat-de-sygnature-discovery-avec-odp2","tag-participation-de-cancer-research-horizons-et-du-mcrc","tag-programme-de-developpement-en-oncologie","tag-reduire-les-risques-et-catalyser-les-innovations-basees-au-royaume-uni"],"acf":[],"yoast_head":"\nSygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-22T10:58:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T09:51:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"pnpd-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"pnpd-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/\"},\"author\":{\"name\":\"pnpd-admin\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\"},\"headline\":\"Sygnature Discovery s’associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni.\",\"datePublished\":\"2022-12-22T10:58:42+00:00\",\"dateModified\":\"2026-02-11T09:51:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/\"},\"wordCount\":645,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/ODP2_Final-image.png\",\"keywords\":[\"Acc\u00e9l\u00e9rer les innovations novatrices en mati\u00e8re de cancer\",\"Approche Lean Life Science pour les actifs en oncologie\",\"Avanc\u00e9es majeures en oncologie r\u00e9alis\u00e9es au Royaume-Uni\",\"Collaboration avec des entreprises pharmaceutiques mondiales\",\"Examen par un panel d'experts r\u00e9dig\u00e9 par Jane Kendrew\",\"Masterclass immersive en \u00e9valuations pharmaceutiques\",\"Partenariat de Sygnature Discovery avec ODP2\",\"Participation de Cancer Research Horizons et du MCRC\",\"Programme de d\u00e9veloppement en oncologie\",\"R\u00e9duire les risques et catalyser les innovations bas\u00e9es au Royaume-Uni\"],\"articleSection\":[\"Domaines th\u00e9rapeutiques\",\"Mod\u00e8les d'oncologie\",\"oncologie\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/\",\"name\":\"Sygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/ODP2_Final-image.png\",\"datePublished\":\"2022-12-22T10:58:42+00:00\",\"dateModified\":\"2026-02-11T09:51:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/ODP2_Final-image.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/ODP2_Final-image.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sygnature Discovery s’associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\",\"name\":\"pnpd-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"caption\":\"pnpd-admin\"},\"sameAs\":[\"http:\\\/\\\/www.sygnaturediscovery.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/","og_locale":"fr_CA","og_type":"article","og_title":"Sygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/","og_site_name":"Sygnature","article_published_time":"2022-12-22T10:58:42+00:00","article_modified_time":"2026-02-11T09:51:11+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png","type":"image\/png"}],"author":"pnpd-admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"pnpd-admin","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#article","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/"},"author":{"name":"pnpd-admin","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448"},"headline":"Sygnature Discovery s’associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni.","datePublished":"2022-12-22T10:58:42+00:00","dateModified":"2026-02-11T09:51:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/"},"wordCount":645,"publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png","keywords":["Acc\u00e9l\u00e9rer les innovations novatrices en mati\u00e8re de cancer","Approche Lean Life Science pour les actifs en oncologie","Avanc\u00e9es majeures en oncologie r\u00e9alis\u00e9es au Royaume-Uni","Collaboration avec des entreprises pharmaceutiques mondiales","Examen par un panel d'experts r\u00e9dig\u00e9 par Jane Kendrew","Masterclass immersive en \u00e9valuations pharmaceutiques","Partenariat de Sygnature Discovery avec ODP2","Participation de Cancer Research Horizons et du MCRC","Programme de d\u00e9veloppement en oncologie","R\u00e9duire les risques et catalyser les innovations bas\u00e9es au Royaume-Uni"],"articleSection":["Domaines th\u00e9rapeutiques","Mod\u00e8les d'oncologie","oncologie"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/","name":"Sygnature Discovery s'associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni. - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png","datePublished":"2022-12-22T10:58:42+00:00","dateModified":"2026-02-11T09:51:11+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/ODP2_Final-image.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-sassocie-au-programme-de-developpement-en-oncologie-odp2-pour-identifier-les-percees-en-oncologie-realisees-au-royaume-uni\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Sygnature Discovery s’associe au Programme de d\u00e9veloppement en oncologie (ODP2) pour identifier les perc\u00e9es en oncologie r\u00e9alis\u00e9es au Royaume-Uni."}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448","name":"pnpd-admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","caption":"pnpd-admin"},"sameAs":["http:\/\/www.sygnaturediscovery.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/comments?post=13781"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13781\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/13782"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/tags?post=13781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}